Novartis sews up Elidel off-label probe with $19.9M deal

Novartis ($NVS) agreed to pay $19.9 million to wrap up federal and state allegations that it marketed its eczema cream Elidel for off-label use. The settlement is a small fraction of other Big Pharma marketing settlements, which have grown into the billions. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.